The RIO-Diabetes study, which was performed in 159 centers in 11 countries, showed that rimonabant 20 mg once daily can reduce body weight and improve cardiovascular and metabolic risk factors in ...

Rimonabant has been shown to produce substantial weight loss and waist circumference reduction in nondiabetic overweight or obese patients, as well as improve their cardiovascular risk factors. Scheen ...

With rimonabant we see an improvement in HbA 1c with important reductions in weight—that is what makes it different and distinct. He believes that rimonabant has "tremendous potential" in the ...

A little pharmacodynamics review. Rimonabant is an inverse agonist at the cannabinoid 1 (CB1) receptor. Briefly, an inverse agonist is a pharmacological agent that binds to a receptor and keeps it ...

Obesity is an important risk factor for metabolic and cardiovascular diseases. Although treatment focuses on improved diet and exercise, pharmacologic intervention might also be beneficial. The ...

An account of the failed investigational weight-loss drug rimonabant, published Thursday, suggests that it may be even harder in the future to bring new prescription diet drugs to the market. The drug ...

CHICAGO – New data demonstrate the efficacy of rimonabant in improving the atherogenic dyslipidemia profile in patients with type 2 diabetes, in addition to reducing weight and improving glycemic ...

SAN FRANCISCO (MarketWatch) -- A Food and Drug Administration advisory panel said Wednesday Sanofi Aventis has failed to demonstrate the safety of its proposed weight-loss drug rimonabant, according ...

Sanofi-Aventis said Friday it has decided to withdraw its New Drug Application (NDA) for weight-loss treatment rimonabant in the US. The decision came just a week and a half after an advisory panel of ...

Treatment with rimonabant may offer significant weight loss benefits for patients who are overweight or obese, according to recent results from the RIO: North America Study. The study, led by F.

Cincinnati, OH, March 9, 2004 - C Researchers at the University of Cincinnati College of Medicine presented results of one of the largest smoking cessation trials ever conducted in the United States, ...

One nutrition specialist says the Acomplia safety ruling goes too far. June 14, 2007 — -- On Wednesday an advisory panel to the U.S. Food and Drug Administration reached the conclusion that ...